A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019.

Autor: Méroc E; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Liang C; Pfizer Inc, Milan, Italy. caihua.liang@pfizer.com.; Pfizer Inc, Dublin, Ireland. caihua.liang@pfizer.com.; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA. caihua.liang@pfizer.com., Iantomasi R; Pfizer Inc, Milan, Italy.; Pfizer Inc, Dublin, Ireland.; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., Onwuchekwa C; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Innocenti GP; Pfizer Inc, Milan, Italy.; Pfizer Inc, Dublin, Ireland.; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., d'Angela D; Centro Per La Ricerca Economica Applicanta in Sanita, Rome, Italy., Molalign S; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Tran TMP; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Basu S; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Gessner BD; Pfizer Inc, Milan, Italy.; Pfizer Inc, Dublin, Ireland.; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., Bruyndonckx R; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Polkowska-Kramek A; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Begier E; Pfizer Inc, Milan, Italy.; Pfizer Inc, Dublin, Ireland.; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA.

Publikováno v: Infectious diseases and therapy [Infect Dis Ther] 2024 Nov; Vol. 13 (11), pp. 2319-2332. Date of Electronic Publication: 2024 Sep 18.

Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.

Autor: Polkowska-Kramek A; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Begier E; Pfizer Inc, Dublin, Ireland., Bruyndonckx R; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Liang C; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA. caihua.liang@pfizer.com., Beese C; Pfizer Pharma GmbH, Berlin, Germany., Brestrich G; Pfizer Pharma GmbH, Berlin, Germany., Tran TMP; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Nuttens C; Pfizer Inc, Paris, France., Casas M; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Bayer LJ; Pfizer Pharma GmbH, Berlin, Germany., Huebbe B; Pfizer Pharma GmbH, Berlin, Germany., Ewnetu WB; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Agudelo JLR; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Gessner BD; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., von Eiff C; Pfizer Pharma GmbH, Berlin, Germany., Rohde G; Medical Clinic I, Department of Respiratory Medicine, Goethe University Frankfurt, University Hospital, Frankfurt/Main, Germany.

Publikováno v: Infectious diseases and therapy [Infect Dis Ther] 2024 Apr; Vol. 13 (4), pp. 845-860. Date of Electronic Publication: 2024 Mar 23.

Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016-2019.

Autor: Haeberer M; Pfizer SL, Av Europa 20B, 28108, Madrid, Spain. mariana.haeberer@pfizer.com., Bruyndonckx R; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Polkowska-Kramek A; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Torres A; Clínic Barcelona Hospital, Barcelona, Spain., Liang C; Pfizer Inc, New York City, USA., Nuttens C; Pfizer Inc, Paris, France., Casas M; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Lemme F; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Ewnetu WB; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Tran TMP; Epidemiology and Pharmacovigilance, P95, Leuven, Belgium., Atwell JE; Pfizer Inc, New York City, USA., Diez CM; Pfizer SL, Av Europa 20B, 28108, Madrid, Spain., Gessner BD; Pfizer Inc, New York City, USA., Begier E; Pfizer Inc, Dublin, Ireland.

Publikováno v: Infectious diseases and therapy [Infect Dis Ther] 2024 Mar; Vol. 13 (3), pp. 463-480. Date of Electronic Publication: 2024 Feb 06.

Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005-2020).

Autor: Burn L; P95 Pharmacovigilance & Epidemiology, Princeton, New Jersey, USA., Tran TMP; P95 Pharmacovigilance & Epidemiology, Leuven, Belgium., Pilz A; Pfizer Global Medical Affairs, Vaccines, Vienna, Austria., Vyse A; Pfizer Vaccines Medical, Walton Oaks, Surrey, United Kingdom., Fletcher MA; Pfizer Emerging Markets Medical Affairs, Vaccines, Paris, France., Angulo FJ; Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA., Gessner BD; Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA., Moïsi JC; Pfizer Medical Development, Scientific and Clinical Affairs, Vaccines, Paris, France., Jodar L; Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA., Stark JH; Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA.

Publikováno v: Vector borne and zoonotic diseases (Larchmont, N.Y.) [Vector Borne Zoonotic Dis] 2023 Apr; Vol. 23 (4), pp. 156-171.

Incidence of Lyme Borreliosis in Europe: A Systematic Review (2005-2020).

Autor: Burn L; P95 Pharmacovigilance and Epidemiology, Princeton, New Jersey, USA., Vyse A; Pfizer Vaccines Medical, Walton Oaks, United Kingdom., Pilz A; Pfizer Global Medical Affairs, Vaccines, Vienna, Austria., Tran TMP; P95 Pharmacovigilance and Epidemiology, Leuven, Belgium., Fletcher MA; Pfizer Emerging Markets Medical Affairs, Vaccines, Paris, France., Angulo FJ; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA., Gessner BD; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA., Moïsi JC; Pfizer Medical Development, Scientific and Clinical Affairs, Vaccines, Paris, France., Stark JH; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer, Inc., Collegeville, Pennsylvania, USA.

Publikováno v: Vector borne and zoonotic diseases (Larchmont, N.Y.) [Vector Borne Zoonotic Dis] 2023 Apr; Vol. 23 (4), pp. 172-194.